Heart Failure - REBIRTH
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Criteria:
- Newly diagnosed women ≥ 18 years of age with PPCM within 5 months postpartum with LVEF ≤ 40%.
- Women who meet eligibility criteria but wish to breastfeed will be eligible for participation in an observational cohort.
Location: Hartford Hospital
Contacts: Khadija El Aoudi 860-972-3167 khadija.elaoudi@hhchealth.org Dr. Jennifer Bell Jennifer.bell@hhchealth.org, Dr. Stephanie Saucier stephanie.saucier@hhchealth.org